Upadacitinib is expected to help AbbVie continue to lead in the immunology market after biosimilar competition emerges for adalimumab in 2023. The approval for the treatment of RA is one of 6 indications that AbbVie’s chief executive officer, Richard Gonzalez, said in a 2018 presentation that the company expects to have approved and launched by 2022.
Drug maker AbbVie has received approval for upadacitinib (Rinvoq), an orally administered Janus kinase (JAK) inhibitor for the treatment of patients with rheumatoid arthritis (RA) who have not responded adequately to methotrexate.
AbbVie expects the drug to become available to US patients later this month. The small-molecule drug, given at a dose of 15 mg once daily, will launch at a list price of $59,000 per patient per year, under the approximately $60,000 per patient per year for AbbVie’s flagship RA therapy, adalimumab (Humira). AbbVie said in a statement that its patient support program and copay card may bring out-of-pocket costs for eligible commercially-insured patients to $5 per month.
Upadacitinib is expected to help AbbVie continue to lead in the immunology market after biosimilar competition emerges for adalimumab in 2023. The approval for the treatment of RA is one of 6 indications that AbbVie’s chief executive officer, Richard Gonzalez, said in a 2018 presentation that the company expects to have approved and launched by 2022.
Upadacitinib was approved on the basis of data from the SELECT program, which enrolled approximately 4400 patients in 5 studies.
In one of those studies, the SELECT-COMPARE study, upadacitinib outperformed both placebo and AbbVie’s blockbuster brand-name adalimumab, Humira, in terms of the proportion of patients who achieved the American College of Rheumatology’s criteria for 20% improvement (ACR20) at week 12. The JAK inhibitor was also superior to adalimumab in terms of the proportion of patients who reached ACR50 at week 12, as well as in reduction of pain and improvement in quality of life as measured by the Health Assessment Questionnaire Disability Index.
The proportion of patients with adverse events (AEs) was higher for those given upadacitinib than those given placebo, but similar to those given adalimumab. Notably, thromboembolic events were similar across the 3 arms; 6 venous thromboembolic events occurred, 1 in the placebo arm, 2 in the upadacitinib arm, and 3 in the adalimumab arm. In a previous phase 3 study in the SELECT clinical program, SELECT-MONOTHERAPY, some concerns arose about the safety of the drug with respect to thromboembolic events.
In its label, upadacitinib carries a boxed warning that indicates that JAK inhibitors as a class have been liked with thrombosis; Pfizer’s tofacitinib (Xeljanz) was recently given a boxed warning on its label noting an increased risk for pulmonary embolism with a 10-mg twice-daily dose of the drug, which is currently approved for patients with ulcerative colitis. Baricitinib (Olumiant) also carries such a boxed warning, and was approved only at the lower of 2 proposed doses after the FDA’s Arthritis Advisory Committee voted against recommending approval of a higher dose given concerns about the potential for dose-dependent adverse events including thrombosis.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.